The high EZH2 expression group was shown to have a significant impact on OS and PFS in patients with gliomas, with a significant decreased OS (mean = 28.2 months, p = 0.007) and PFS (mean = 9.7 months, p < 0.001) compared to the low EZH2 expression group (mean OS = 73.663 months, p = 0.007, and mean PFS = 43.7 months, p < 0.001). Here, EZH2 is linked to central nervous system cancer.